Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Henry Meds vs Ilant Health

Henry Meds
Graded #46

Higher grade

vs+20.5
Ilant Health
Graded #408

Lower grade

The verdict

Henry Meds takes it — 77.3/100 to 56.8/100.

Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A flat-fee compounded pioneer — simple, but priced at the higher end of the board now.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHenry Meds +27
72
45
Dose & formulationHenry Meds +40
80
40
Clinical oversightIlant Health +3
80
83
Labs & monitoringHenry Meds +17
78
61
FulfillmentHenry Meds +16
78
62
Contract termsHenry Meds +23
78
55
Henry Meds · left barIlant Health · right bar

The numbers

MetricHenry MedsIlant Health
WeighScore77.3/10056.8/100
GradeC+C
Scorecard rank#46#408
Semaglutide$249/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageMulti-stateCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Henry Meds

Graded #46 · C+

Strengths

  • Simple flat-fee model
  • Established brand
  • Both molecules

Where it loses points

  • Higher pricing than newer entrants
  • Compounded only
Ilant Health

Graded #408 · C

Strengths

  • Value-based, outcomes-driven obesity care model
  • Includes GLP-1 medications with transparent drug pricing for sponsors
  • Care team of board-certified obesity providers and behavioral specialists
  • Dietitians and peer navigators support adherence
  • Data-driven stratification targets the right interventions

Where it loses points

  • Distributed via employers and health plans, not direct cash-pay
  • Individuals generally cannot enroll without sponsor coverage
  • No public consumer pricing for GLP-1
  • Access gated behind organizational buyers
  • Not suited to consumers wanting direct-to-door GLP-1

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard